The year in cardiovascular medicine 2021: heart failure and cardiomyopathies - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34974611/
In the year 2021, the universal definition and classification of heart failure (HF) was published that defines HF as a clinical syndrome with symptoms and/or signs caused by a cardiac...
Conclusion: In patients hospitalized with COVID-19, acute HF and myocardial injury is quite frequent, whereas myocarditis and long-term damage to the heart are rather uncommon.
Early Benefit with Empagliflozin in Heart Failure with Preserved Ejection Fraction Insights from the EMPEROR‐Preserved Trial
Source : https://onlinelibrary.wiley.com/doi/10.1002/ejhf.2420
Javed Butler , Corresponding Author Javed Butler Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi, US Corresponding author. Javed Butler, MD MPH MBA. University of Mississippi Medical Center,...
Conclusion/Relevance: Our results reinforce the importance of early initiation of treatment in patients with HFpEF.
Hepatoprotective effects of gemigliptin and empagliflozin in a murine model of diet-induced non-alcoholic fatty liver disease - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34971904/
1 Department of Endocrinology and Metabolism, Ajou University School of Medicine, 164 Worldcup-ro, Yeoungtong-gu, Suwon, 16499, Republic of Korea. 2 Department of Physiology, Ajou University School of Medicine, 164 Worldcup-ro,...
Conclusion: These findings suggest that the GEMI, EMPA, and GEMI EMPA treatments ameliorate hepatic steatosis, inflammation, oxidative stress, and fibrosis in CDAHFD-induced NAFLD mouse models.
Prognostic Value of Multiple Circulating Biomarkers for 2-Year Death in Acute Heart Failure With Preserved Ejection Fraction
Source : https://www.frontiersin.org/articles/10.3389/fcvm.2021.779282/full
Background: Heart failure with preserved ejection fraction (HFpEF) is increasingly recognized as a major global public health burden and lacks effective risk stratification. We aimed to assess a multi-biomarker model...
Conclusions: Multiple circulating biomarkers coupled with an appropriate machine-learning method could effectively predict the risk of long-term mortality in patients with acute HFpEF. It is a promising strategy for improving risk stratification in HFpEF.
Rationale and design of the effects of EMpagliflozin on left ventricular DIAstolic function in diabetes (EmDia) study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34939776/
doi: 10.2459/JCM.0000000000001267. Online ahead of print. 1 Preventive Cardiology and Preventive Medicine, Department of Cardiology. 2 Department of Psychosomatic Medicine and Psychotherapy, University Medical Center of the Johannes Gutenberg-University Mainz....
Conclusion: By evaluating the short-term effect of empagliflozin with a comprehensive biobanking program, the EmDia Study offers an opportunity to primarily assess the effects on diastolic function but also to examine effects on clinical and molecular cardiovascular traits.